Dr. Phoebe Joy Ho is presenting the results of the CAMMA 3 trial, which evaluates cevostamab in relapsed/refractory #myeloma (#RRMM), at #ASH2025.

Juan Du MD presenting interesting results on AZD0120 dual targeting (BCMA/CD19) CAR-T using FasTCAR manufacturing. #myeloma #CAR-T

Iberdomide is a CELMoD drug being explored in #myeloma. Niels Van De Donk highlighted @emnmyeloma.bsky.social #EMN26 Phase 2 data on use as a post transplant maintenance therapy in NDMM.

#ASH25

MPE is at #ASH2025, starting with #myeloma oral session on MRD and maintenance therapy, double hit HR-MM, iberdomide, carfilzomb and sonrotoclax treatments.

If you want to know more about the #myeloma updates presented at #ASH2025, don't miss our post-ASH webinar, on Wednesday 17 December. Register now!👇
www.mpeurope.org/mpe-webinar-...

@ash.hematology.org @emnmyeloma.bsky.social @europeancancer.bsky.social @eortc.org

Katie Joyner, co-CEO of MPE, is highlighting how this programme provides psychological, legal and social support through a multidisciplinary care model.

MPE starts #ASH2025 by presenting APCL Cares, a comprehensive psychosocial support programme developed by the Portuguese Association Against Leukaemia (APCL).

MPE is attending the @ash.hematology.org annual congress in Orlando, Florida. Over the next few days, we will follow the key updates in #myeloma and #ALamyloidosis and speak with leading experts to understand what they mean for patients.
#ASH25